賽升藥業(300485.SZ)取得藥品生產許可證 涉生產地址和範圍的新增
格隆匯12月19日丨賽升藥業(300485.SZ)公佈,公司於2019年12月19日取得北京市藥品監督管理局頒發的《藥品生產許可證》,此次主要涉及生產地址和範圍的新增,生產地址和生產範圍:北京市北京經濟技術開發區興盛街8號;小容量注射劑;凍乾粉針劑(含激素類);北京市北京經濟技術開發區河西區X20F2地塊;小容量注射劑;凍乾粉針劑(含激素類)。
此次《藥品生產許可證》變更涉及新增募投生產基地項目的生產地址和生產範圍,後期公司將推動新增地址的產品生產線的驗證工作,有利於公司產品轉移工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.